A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Between 2000 and 2005 several studies revealed that morphine is more potent and exhibits fewer side effects in beta-arrestin 2 knockout mice. These findings spurred efforts to develop opioids that signal primarily via G protein activation and do not, or only very weakly, recruit beta-arrestin. Devel...
Saved in:
Main Authors: | Kendall L. Mores (Author), Benjamin R. Cummins (Author), Robert J. Cassell (Author), Richard M. van Rijn (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects
by: Alexander R. French, et al.
Published: (2022) -
Exploration of beta-arrestin isoform signaling pathways in delta opioid receptor agonist-induced convulsions
by: Arryn T. Blaine, et al.
Published: (2022) -
Evaluation of Kratom Opioid Derivatives as Potential Treatment Option for Alcohol Use Disorder
by: Anna M. Gutridge, et al.
Published: (2021) -
ClickArr: a novel, high-throughput assay for evaluating β-arrestin isoform recruitment
by: Alexander R. French, et al.
Published: (2023) -
Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors
by: Yazan J. Meqbil, et al.
Published: (2022)